A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.

NCT05704634 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Cemiplimab
DRUG: Kevzara (Sarilumab)

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]